These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1567 related items for PubMed ID: 26588909

  • 1. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
    Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.
    Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
    Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.
    Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
    [Abstract] [Full Text] [Related]

  • 3. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
    Tsentidis C, Gourgiotis D, Kossiva L, Marmarinos A, Doulgeraki A, Karavanaki K.
    Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
    [Abstract] [Full Text] [Related]

  • 4. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM.
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [Abstract] [Full Text] [Related]

  • 5. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
    Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.
    Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
    [Abstract] [Full Text] [Related]

  • 6. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L, Ruiz-Gaspà S, Carrasco JL, Portell E, Vidal J, Muxi A, Monegal A, Guañabens N, Peris P.
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [Abstract] [Full Text] [Related]

  • 7. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
    Ali R, Hammad A, El-Nahrery E, Hamdy N, Elhawary AK, Eid R.
    Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
    [Abstract] [Full Text] [Related]

  • 8. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Sep; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 9. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
    Menopause; 2009 Sep; 16(5):950-5. PubMed ID: 19387415
    [Abstract] [Full Text] [Related]

  • 10. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N.
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [Abstract] [Full Text] [Related]

  • 11. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
    Xu S, Wang Y, Lu J, Xu J.
    Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
    [Abstract] [Full Text] [Related]

  • 12. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M, Fathy SA, Mehany NL, Hindy OW.
    Clin Chem Lab Med; 2007 Nov; 45(11):1498-503. PubMed ID: 17970704
    [Abstract] [Full Text] [Related]

  • 13. OPG/RANK/RANKL signaling axis in patients with type I diabetes: Associations with parathormone and vitamin D.
    Karalazou P, Ntelios D, Chatzopoulou F, Fragou A, Taousani M, Mouzaki K, Galli-Tsinopoulou A, Kouidou S, Tzimagiorgis G.
    Ital J Pediatr; 2019 Dec 10; 45(1):161. PubMed ID: 31823791
    [Abstract] [Full Text] [Related]

  • 14. Low bone mineral density is associated to poor glycemic control and increased OPG expression in children and adolescents with type 1 diabetes.
    Loureiro MB, Ururahy MA, Freire-Neto FP, Oliveira GH, Duarte VM, Luchessi AD, Brandão-Neto J, Hirata RD, Hirata MH, Maciel-Neto JJ, Arrais RF, Almeida MG, Rezende AA.
    Diabetes Res Clin Pract; 2014 Mar 10; 103(3):452-7. PubMed ID: 24529565
    [Abstract] [Full Text] [Related]

  • 15. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
    Honsawek S, Chaiwatanarat T, Vejchapipat P, Chongsrisawat V, Thawornsuk N, Poovorawan Y.
    Pediatr Surg Int; 2009 Mar 10; 25(3):261-7. PubMed ID: 19184056
    [Abstract] [Full Text] [Related]

  • 16. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N.
    Liver Int; 2007 May 10; 27(4):492-7. PubMed ID: 17403189
    [Abstract] [Full Text] [Related]

  • 17. Carotid intima media thickness and associations with serum osteoprotegerin and s-RANKL in children and adolescents with type 1 diabetes mellitus with increased risk for endothelial dysfunction.
    Karavanaki K, Tsouvalas E, Vakaki M, Soldatou A, Tsentidis C, Kaparos G, Augoulea A, Alexandrou A, Lambrinoudaki Ι.
    J Pediatr Endocrinol Metab; 2018 Nov 27; 31(11):1169-1177. PubMed ID: 30352039
    [Abstract] [Full Text] [Related]

  • 18. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution.
    Fichna M, Zurawek M, Fichna P, Gryczynska M, Nowak J, Ruchala M.
    J Physiol Pharmacol; 2012 Dec 27; 63(6):677-82. PubMed ID: 23388484
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis.
    Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP.
    J Clin Pathol; 2011 Apr 27; 64(4):354-7. PubMed ID: 21307155
    [Abstract] [Full Text] [Related]

  • 20. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
    Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
    Ther Apher Dial; 2009 Feb 27; 13(1):49-55. PubMed ID: 19379170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.